On 5 November 2020, the High Court of Australia refused a special leave application by Mylan Health Pty Ltd to appeal the decision of the Full Federal Court (FFC) in which three patents licensed to Mylan covering its fenofibrate product, Lipidil, were found to be...
The Australian Patent Office, in Ono Pharmaceutical Co., Ltd. et al [2020] APO 43, has emphatically confirmed that a patent term extension (PTE) request must be based on the first regulatory approval of a product covered by the claims, even if it is a competitor...
His scholarship focuses on philosophy and the history of ideas. His published works include: “Plotinus, Self and the World”, which addresses the question of the individual subject in its relationship with the world; and “French philosophers in conversation”, a...
The enlarged bench of the Full Court of the Australian Federal Court has clarified what constitutes infringement of Swiss-style claims in Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd [2020] FCAFC 116 (the Mylan decision). However, in doing so the Court walks a...
